Memantine Hydrochloride Chanelle Medical (Memantine Hydrochloride)

Memantine Hydrochloride is an NMDA receptor antagonist used in the management of Alzheimer’s disease and related cognitive disorders.

• Moderate to severe Alzheimer’s disease: improves cognition, memory, and daily functioning in patients with significant disease progression.
• Alzheimer’s disease as adjunct therapy: enhances the therapeutic effect when combined with cholinesterase inhibitors.
• Mild to moderate Alzheimer’s disease: may support cognitive function and delay functional decline.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor. By binding to the receptor-associated ion channel with moderate affinity, it blocks excessive calcium influx caused by prolonged glutamate activation, thereby reducing excitotoxic neuronal injury and supporting neuronal survival in the brain.

Memantine Hydrochloride may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Headache: mild to moderate pain in the head region.
• Constipation: reduced bowel movements or hard stools.
• Confusion: transient difficulty concentrating or disorientation.
• Somnolence: feeling unusually sleepy or fatigued.

Serious or Rare Side Effects

• Seizures: rare occurrence of convulsive episodes.
• Severe allergic reactions: rash, itching, swelling, or difficulty breathing.
• Stevens‑Johnson syndrome: rare skin blistering and mucosal involvement.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Cardiac arrhythmias: irregular heart rhythms reported in isolated cases.

When prescribing Memantine Hydrochloride, clinicians should consider several safety factors.

• Renal impairment: adjust dose or monitor closely in patients with reduced kidney function.
• Hepatic impairment: use with caution and assess liver function periodically.
• History of seizures: evaluate risk as memantine may lower seizure threshold.
• Concomitant NMDA antagonists: avoid combining with other agents that block NMDA receptors.
• Pregnancy and breastfeeding: safety not established; weigh potential benefits against risks.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Memantine Hydrochloride can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Amantadine: additive NMDA antagonism may increase neuropsychiatric effects.
• Ketamine: combined NMDA blockade can enhance central nervous system depression.
• Dextromethorphan: may potentiate dizziness and confusion.
• High‑dose anticholinesterase inhibitors: risk of excessive cholinergic activity.
• Strong CYP450 inhibitors: may alter memantine clearance.

Moderate Interactions (Monitor Closely)

• Diuretics: may affect renal excretion of memantine.
• Antihypertensives: monitor blood pressure for additive hypotensive effects.
• Other psychotropic agents: observe for increased sedation or cognitive changes.